Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Reform Bill's Part D Changes Would Boost Premiums 20% By 2019, CBO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

However, the cost to beneficiaries of increased premiums would be offset, on average, by the lower cost-sharing that would result from the legislation, CBO adds.

You may also be interested in...



House Health Reform Bill Nets $48 Bil. From Pharma - CBO

The Congressional Budget Office has put a value on the net savings that would accrue to the federal government through drug rebate and discount provisions in the pending House health care reform bill: $48 billion over 10 years

House Bill Would Expand Rx Market, But Negatives Draw PhRMA's Protest

The House health care reform bill contains a number of provisions that would greatly expand the market for pharmaceuticals, but the bill seeks a number of financial concessions from pharmaceutical manufacturers, prompting a statement of protest from the industry association

Revlimid And Copaxone Pricing: Five Not-So-Revealing Revelations From The House Reports

Investigative reports from the House Oversight and Reform Committee recount well-known records of significant price increases for the drugs, the lack of pricing restraints in the US relative to markets abroad, tactics used to protect the drugs from generic competition and the 'return on investment' from manufacturer assistance programs.

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel